Replies to post #6441 on Halozyme Therapeutics Inc (HALO)

[maumar]

I am very bullish on Darzalex Faspro and pretty bullish on Phesgo but I am also concerned about the following:

1. I agree that the convertible issue creates overhang and will be a positive only if they make a brilliant acquisition, which of course is no sure thing. The potential acquisition also makes me nervous because it makes you wonder, if Halo thinks Enhanze is so great and is not concerned about its patents' expiry, why do they want/need another platform/technology?

2. I am concerned our royalties are heavily reliant on Darzalex Faspro. Could it be 70%, perhaps even higher? Does anybody have an educated guess? In any case, any slowdown in Darzalex revenue growth could really hurt us unless Phesgo surpasses expectations and/or we sign several new deals, we have more phase 3 trial starts, etc.

3. When will we get a new product approved? Will it be close to Jan 2023 or closer to Dec 2025?

4. I believe Halo has signed only two new deals, with Horizon (Nov 2020) and with Argenx (Feb 2019) since the deals with ALXN and BMY in 2017. Why haven't there been more new collaborations?